



C-RAD receives an order of 12 MSEK from Italy, related to an extension of the national Consip tender

Tecnosan S.r.l., C-RAD's Italian distributor, has placed an order to C-RAD amounting to 12 MSEK for multiple Catalyst+ HD units. The order is connected to the national tender that was awarded in 2022, managed by the Italian health authorities and e-procurement group Consip, where Tecnosan ranked first in the lot for SGRT system in linac/treatment rooms and third in the gating lot.

As announced in December 2022, Tecnosan's placement as primary supplier led to an order amounting to 46 MSEK. Recently, due to a high demand of SGRT solutions in the country and installation activities of many units proceed apace, the SGRT lot availability has been extended by 30%, leading to a new order of 12 MSEK to C-RAD and to more hospitals that will be equipped with SGRT technology.

Delivery and installation of the systems are expected to take place from Autumn 2024 to the end of the Summer 2025.

Cecilia de Leeuw, CEO and president of C-RAD, comments:

"I would like to congratulate the Tecnosan team for the tremendous effort they are putting into installing a significant number of SGRT systems and training new users in a short period of time. We are very proud of this long-lasting partnership. I would also acknowledge the massive adoption of SGRT technology across the country and seeing the Italian C-RAD network growing."

Mattia Dell'Orsola, CEO of Tecnosan, says:

"In the past 11 years of partnership with C-RAD, we have been devoted to our efforts on radiotherapy and SGRT. Our commitment in this direction has also been rewarded with this important order. I would like to personally thank our team for the work they do every day with professionalism and enthusiasm, thanks to which we have introduced the use of SGRT systems to users across the country."

The extension of the national tender provides further evidence that SGRT is a standard of care in Italy and is becoming an indispensable tool for radiotherapy departments in order to perform positioning, motion monitoring and Deep Inspiration Breath Hold treatments.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com

Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com

Press Release
21 March 2024 12:30:00 CET



About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

[C-RAD receives an order of 12 MSEK from Italy, related to an extension of the national Consip tender](#)